LONG NAGOMI™ PMCF STUDY

Summary

The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.

Eligibility

Inclusion Criteria:

* Patients who meet ALL inclusion criteria will be included:
* Patients aged ≥ 18 years AND;
* Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;
* Patients with at least one lesion fulfilling the "long lesion criteria" suitable for a single stent approach AND;
* Patients who have been informed of the characteristics of the study and have provided written informed consent AND;
* Intention to treat all lesions with the Ultimaster Nagomi™ stent

Exclusion Criteria:

* Patients must not meet any of the following exclusion criteria:
* Patients who expressly decline to participate in the study.
* Pregnant or breastfeeding women.
* Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4).
* Patients with contraindications or hypersensitivity to sirolimus.
* Patients with a life expectancy of less than 2 years.
* Patients in whom any surgery requiring general anesthesia is planned, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines.
* Patients included in other clinical trials that did not reach the primary objective.

Conditions3

Browse More Trials